365 related articles for article (PubMed ID: 28065582)
21. Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model.
Thomsen K; Christophersen L; Bjarnsholt T; Jensen PØ; Moser C; Høiby N
J Cyst Fibros; 2016 Mar; 15(2):171-8. PubMed ID: 26303991
[TBL] [Abstract][Full Text] [Related]
22. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ
Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice.
Campodónico VL; Llosa NJ; Bentancor LV; Maira-Litran T; Pier GB
Infect Immun; 2011 Aug; 79(8):3455-64. PubMed ID: 21628521
[TBL] [Abstract][Full Text] [Related]
24. Passive immunization against Pseudomonas aeruginosa recombinant PilA in a murine burn wound model.
Mousavi M; Behrouz B; Irajian G; Mahdavi M; Korpi F; Motamedifar M
Microb Pathog; 2016 Dec; 101():83-88. PubMed ID: 27836762
[TBL] [Abstract][Full Text] [Related]
25. New possibility for providing protection against urinary tract infection caused by Pseudomonas aeruginosa by non-adjuvanted flagellin 'b' induced immunity.
Sabharwal N; Chhibber S; Harjai K
Immunol Lett; 2014 Dec; 162(2 Pt B):229-38. PubMed ID: 25455605
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy with IgY Antibodies toward Outer Membrane Protein F Protects Burned Mice against
Norouzi F; Behrouz B; Ranjbar M; Mousavi Gargari SL
J Immunol Res; 2020; 2020():7840631. PubMed ID: 32566689
[TBL] [Abstract][Full Text] [Related]
27. Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by Pseudomonas aeruginosa.
Golpasha ID; Mousavi SF; Owlia P; Siadat SD; Irani S
Bosn J Basic Med Sci; 2015 May; 15(2):15-24. PubMed ID: 26042508
[TBL] [Abstract][Full Text] [Related]
28. The role of flagellin versus motility in acute lung disease caused by Pseudomonas aeruginosa.
Balloy V; Verma A; Kuravi S; Si-Tahar M; Chignard M; Ramphal R
J Infect Dis; 2007 Jul; 196(2):289-96. PubMed ID: 17570117
[TBL] [Abstract][Full Text] [Related]
29. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.
Weimer ET; Lu H; Kock ND; Wozniak DJ; Mizel SB
Infect Immun; 2009 Jun; 77(6):2356-66. PubMed ID: 19349426
[TBL] [Abstract][Full Text] [Related]
30. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.
DiGiandomenico A; Keller AE; Gao C; Rainey GJ; Warrener P; Camara MM; Bonnell J; Fleming R; Bezabeh B; Dimasi N; Sellman BR; Hilliard J; Guenther CM; Datta V; Zhao W; Gao C; Yu XQ; Suzich JA; Stover CK
Sci Transl Med; 2014 Nov; 6(262):262ra155. PubMed ID: 25391481
[TBL] [Abstract][Full Text] [Related]
31. In-Silico Analysis and Protective Efficacy of the PcrV Recombinant Vaccine against Pseudomonas Aeruginosa in the Burned and PA-Infected BALB/c Mouse Model.
Fakoor MH; Owlia P; Mousavi Gargari SL; Sabokbar A
Iran J Immunol; 2020 Jun; 17(2):121-136. PubMed ID: 32602466
[TBL] [Abstract][Full Text] [Related]
32. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
Zaidi TS; Priebe GP; Pier GB
Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
[TBL] [Abstract][Full Text] [Related]
33. Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous
Liu C; Pan X; Xia B; Chen F; Jin Y; Bai F; Priebe G; Cheng Z; Jin S; Wu W
Front Immunol; 2018; 9():1737. PubMed ID: 30093906
[No Abstract] [Full Text] [Related]
34. Interleukin 7 immunotherapy improves host immunity and survival in a two-hit model of Pseudomonas aeruginosa pneumonia.
Shindo Y; Fuchs AG; Davis CG; Eitas T; Unsinger J; Burnham CD; Green JM; Morre M; Bochicchio GV; Hotchkiss RS
J Leukoc Biol; 2017 Feb; 101(2):543-554. PubMed ID: 27630218
[TBL] [Abstract][Full Text] [Related]
35. MEDI3902 Correlates of Protection against Severe Pseudomonas aeruginosa Pneumonia in a Rabbit Acute Pneumonia Model.
Le HN; Quetz JS; Tran VG; Le VTM; Aguiar-Alves F; Pinheiro MG; Cheng L; Yu L; Sellman BR; Stover CK; DiGiandomenico A; Diep BA
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483116
[No Abstract] [Full Text] [Related]
36. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.
Horn MP; Zuercher AW; Imboden MA; Rudolf MP; Lazar H; Wu H; Hoiby N; Fas SC; Lang AB
Antimicrob Agents Chemother; 2010 Jun; 54(6):2338-44. PubMed ID: 20308370
[TBL] [Abstract][Full Text] [Related]
37. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge.
Neely AN; Holder IA; Wiener-Kronish JP; Sawa T
Burns; 2005 Mar; 31(2):153-8. PubMed ID: 15683685
[TBL] [Abstract][Full Text] [Related]
38. Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin.
Ramphal R; Balloy V; Jyot J; Verma A; Si-Tahar M; Chignard M
J Immunol; 2008 Jul; 181(1):586-92. PubMed ID: 18566425
[TBL] [Abstract][Full Text] [Related]
39. A specific serum IgA antibody discriminates pneumonia from colonization state in patients with Pseudomonas aeruginosa in sputum culture.
Yamashita M; Hida Y; Sugimoto H; Takahashi N; Kimura H; Nakatomi Y; Yoshida H; Ishizaki T
J Microbiol Methods; 2010 Sep; 82(3):198-204. PubMed ID: 20538018
[TBL] [Abstract][Full Text] [Related]
40. Generation and characterization of murine antiflagellum monoclonal antibodies that are protective against lethal challenge with Pseudomonas aeruginosa.
Rosok MJ; Stebbins MR; Connelly K; Lostrom ME; Siadak AW
Infect Immun; 1990 Dec; 58(12):3819-28. PubMed ID: 2123821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
